ATRC
$47.81
Atricure
($.75)
(1.54%)
ATRC
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.68)
Revenue:  $34.56 Mil
Wednesday
Jul 29
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, April 29, 2020

What do you expect when ATRC reports earnings?
Beat
Meet
Miss

Where is ATRC's stock price going from here?
Up
Flat
Down
Stock chart of ATRC
Analysts
Summary of analysts' recommendations for ATRC
Score
Grade
Pivots
Resistance
$50.80
$49.98
$48.90

$48.08

Support
$47.00
$46.18
$45.10
Tweet
Growth
Description
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
Peers
StrykerBoston ScientificAbbottBecton, DickinsonBaxter InternationalWatersIntegra LifeSciences HoldingsTeleflex3MAbiomed